A phase 2 study of intratumoral tavokinogene telseplasmid (tavo) plus electroporation with pembrolizumab in patients with inoperable locally advanced or metastatic triple negative breast cancer Meeting Abstract

cited authors

  • Telli, M. L.; Wapnir, I.; Vinayak, S.; Chang, J.; Alemany, C.; Twitty, C.; Gargosky, S.

authors

Publication Date

  • February 1, 2019

webpage

published in

category

volume

  • 79

issue

  • 4